OLIVEIRA, MARIA J.A. deMAIA, REGINABRAZ, LUCIA A.LUGAO, ADEMAR B.AMATO, VALDIR S.PARRA, DUCLERC F.2017-03-162017-03-162016OLIVEIRA, MARIA J.A. de; MAIA, REGINA; BRAZ, LUCIA A.; LUGAO, ADEMAR B.; AMATO, VALDIR S.; PARRA, DUCLERC F. Topical treatment of cutaneous leishmaniasis: wound reduction in mice using n-methyl glucamine from pvp and nano clay membranes. <b>Journal of Dermatology Research and Therapy</b>, v. 2, n. 5, p. 1-4, 2016. DOI: <a href="https://dx.doi.org/10.23937/2469-5750/1510036">10.23937/2469-5750/1510036</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/27174.2469-5750http://repositorio.ipen.br/handle/123456789/27174Biomaterials comprise a scientific field where synthetic materials are developed for pertinent biological functions, yielding a wide diversity of new products. Although widely employed, they still require improvement for therapeutic purposes. The objective of this study was to develop poly (N-2-vinyl-pyrrolidone) (PVP), poly (vinyl alcohol) (PVAl), clay, and N-methyl glucamine hydrogels for the treatment of cutaneous leishmaniasis. The characterization techniques used were tumescence, energy-dispersive X-ray (EDX) spectroscopy. Clay and antimoniate were found to disperse homogeneously in the polymeric matrix. Evaluation of cytotoxicity showed negative result. The in vivo tests used 12 BALB/c infected with 3 × 104 amastigotes/mL of L. (L.) amazonensis. All mice (4/4) from group II presented reduction of diameter wounds after submitted to PVP, PVAl, clay (1,5%), and N-methyl glucamine (2.3 mg) hydrogels, differently from group I PVP, PVAl, and N-methyl glucamine (1 mg) and III (control). Classified as results of a clinical cure, drug release was efficient and such a matrix is a potential contributor to an alternative human therapy capable of increasing the quality of life of a patient who cannot use medication in the conventional way because of side effects.1-4openAccesshydrogelsskinwoundstherapynitratesglucosaminemethyl radicalsmiceArtigo de periódico5210.23937/2469-5750/1510036https://orcid.org/0000-0002-7626-880Xhttps://orcid.org/0000-0002-1737-3191